At Wuhan YZY Biopharma we have developed an asymmetrical BsAb platform called YBODY® (see the Figure or linked to structure) with one arm binding to the specific protein of a cancer cell (a target site) and the other arm binding to CD3 onT-cells (an effector site). The binding of CD3 activates the T-cells, pulls the T-cells close to the cancer cells, and thus, enhances killing the cancer cells by the T cells. As its advantage as bellow (or linked to advantage),BsAbs have become the most attractive biologics for cancer therapy.
1、Whole IgG: PK /PD and bioprocess similar to a mAb
2、Fc with Knob-in-hole and salt bridges: high heterodimer production with limited homodimers
3、CD3 scFv format: ideal for T redirected BsAb
4、Unique MOA: high potency with reduce in recurrence
5、Low dosage: largely reduce side effects and production cost
6、Platform: expandable to variety of targets and effectors